We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 20.00 | 1.95% | 1,047.00 | 414,535 | 16:35:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,049.00 | 1,054.00 | 1,070.00 | 1,011.00 | 1,011.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 1.19B | USD 2M | USD 0.0160 | 657.50 | 1.28B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:45:59 | O | 143 | 1,503.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/6/2025 | 16:42 | UK RNS | Indivior PLC Holding(s) in Company |
| 13/6/2025 | 08:10 | UK RNS | Indivior PLC Director/PDMR Shareholding - Correction |
| 12/6/2025 | 16:24 | UK RNS | Indivior PLC Director/PDMR Shareholding |
| 10/6/2025 | 16:12 | UK RNS | Indivior PLC Holding(s) in Company |
| 06/6/2025 | 16:49 | UK RNS | Indivior PLC Holding(s) in Company |
| 02/6/2025 | 10:48 | ALNC |  Indivior to leave London Stock Exchange in July to focus on US listing |
| 02/6/2025 | 07:00 | UK RNS | Indivior PLC Indivior Announces Intent to Cancel LSE Listing |
| 15/5/2025 | 15:30 | UK RNS | Indivior PLC Director/PDMR Shareholding |
| 13/5/2025 | 15:00 | UK RNS | Indivior PLC Indivior to Participate in Upcoming Events |
| 09/5/2025 | 16:37 | UK RNS | Indivior PLC Amendment to Result of AGM |
Indivior (INDV) Share Charts1 Year Indivior Chart |
|
1 Month Indivior Chart |
Intraday Indivior Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/6/2025 | 15:14 | INDIVIOR THE PILL WITH NO CHEERS OR BEERS | 4,278 |
| 09/3/2020 | 10:34 | RB. de-merger | 548 |
| 11/7/2019 | 08:29 | Johnson & Johnson court case oklahoma | 6 |
| 03/5/2019 | 10:16 | Judgement against insys | 2 |
| 31/7/2018 | 13:45 | Indivior (INDV) IP Battle Status | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-06-20 17:10:27 | 1,503.00 | 143 | 2,149.29 | O |
| 2025-06-20 17:10:26 | 1,194.00 | 202 | 2,411.88 | O |
| 2025-06-20 17:10:25 | 1,578.00 | 13 | 205.14 | O |
| 2025-06-20 17:10:19 | 1,216.00 | 9 | 109.44 | O |
| 2025-06-20 17:10:01 | 1,637.00 | 474 | 7,759.38 | O |
| Top Posts |
|---|
Posted at 21/6/2025 09:20 by Indivior Daily Update Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 1,027p.Indivior currently has 124,758,946 shares in issue. The market capitalisation of Indivior is £1,312,464,112. Indivior has a price to earnings ratio (PE ratio) of 657.50. This morning INDV shares opened at 1,011p |
Posted at 02/6/2025 09:21 by gibbs1 Blow to City as pharma group quits London after share price plungeIndivior to cancel secondary listing on the LSE to focus on Nasdaq By MIKE SHEEN THISISMONEY Updated: 08:57 BST, 2 June 2025 Indivior is set to delist from the London Stock Exchange after a sharp decline in the value of its shares and a management shake-up earlier this year. The pharmaceutical group, known for its opioid addiction treatments, said on Monday it would cancel its secondary listing on the LSE at the end of July and maintain a primary listing on the Nasdaq. Indivior, which switched its primary listing from the UK to the US last year, told investors the decision to quit London would help cut costs. The firm also took aim at London's weak liquidity and trading volumes, and high administrative costs relative to the New York exchange. Indivior floated in London after being spun-out from Reckitt Benckiser in 2014, with its share price rocketing from 725p to 2,450p by June 2018. However, shares have slumped more than 60 per cent from their peak, trading at 944.5p at Friday close. Indivior also said a solo primary listing better reflects the fact it generates more than 80 per cent of net revenues in the US, which is also home to around 70 per cent of its investors. Shares will cease trading in London after roughly 40 business days, with the delisting pencilled in from 8am on 25 July. The decision comes just months after Indivior overhauled its management, with the group appointing David Wheadon as chair and Joe Ciaffoni as chief executive. Wheadon said on Monday the decision to delist from London was a 'key milestone for Indivior'. He added 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' |
Posted at 02/6/2025 07:35 by waldron Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained02/06/2025 7:00am PR Newswire (US) Indivior (NASDAQ:INDV) Intraday Stock Chart Monday 2 June 2025 Click Here for more Indivior Charts. SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Indivior (PRNewsfoto/Indivior Background to and Reasons for the London Delisting In the circular published by Indivior on May 3, 2024, the Board noted its intention to maintain the Company's secondary listing in London, "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Following the completion of Indivior's transition to a U.S. primary listing, the Board has kept its listing structure under regular review. As part of such review, the Company has considered, among other things, the liquidity and trading volumes of Ordinary Shares on each of the Nasdaq Stock Market ("Nasdaq") and the LSE, the location of its shareholders, as well as the cost and administrative requirements related to its secondary listing in London. In further consideration of Indivior's listing structure, the Board now believes that the London Delisting will be beneficial for the following reasons: Fully aligns with Indivior's most attractive and valuable opportunity set – U.S. SUBLOCADE; Better reflects the Company's geographic net revenue profile; over 80% of net revenue is generated from the U.S.; Eliminates the cost and complexity of maintaining a secondary listing; Recognizes that liquidity on Nasdaq now far outweighs liquidity on the LSE; as of May 27th, trading on the Nasdaq now accounts for approximately 75% of total trading volume across both exchanges over the last 30 days; Takes account of the location of most holders of Ordinary Shares by value; over 70% are now held by shareholders located in the U.S.; and Permits timing of material news announcements that aligns with the Company's U.S. peer set. Accordingly, the Company hereby gives notice that it has requested that: (i) the FCA cancel the listing of the Ordinary Shares on the Equity Shares (Transition) category of the Official List of the FCA; and (ii) the LSE cancel the admission to trading of the Ordinary Shares on the main market for listed securities of the LSE. David Wheadon, Chair, said: "We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." Process for and principal effects of the London Delisting In accordance with U.K. Listing Rule 21.2.17R, the Company is required to give at least 20 business days' notice of the London Delisting. To further accommodate shareholders of Indivior PLC, the Company is providing approximately 40 business days' notice of the London Delisting. As such, it is intended that the London Delisting will become effective from 8:00 a.m. (U.K. time) on July 25, 2025, such that the last day of trading of the Ordinary Shares on the LSE will be July 24, 2025. Following the London Delisting: (i) it will no longer be possible to trade Ordinary Shares on the LSE; and (ii) the Company will maintain its listing of its Ordinary Shares on Nasdaq. The London Delisting is expected to have no impact for shareholders who are direct holders of Ordinary Shares or who hold their interests in Ordinary Shares through their nominated DTC broker or custodian. Holders of U.K. issued Indivior Depositary Interests ("U.K. DIs") and participants in Indivior's Corporate Sponsored Nominee facility ("CSN") are strongly encouraged to read Appendix 1 to this announcement, which contains further details of the arrangements that will apply to them following the London Delisting and the actions that they may wish to take in advance of the London Delisting (including the steps and actions required to convert their interests into holdings of Ordinary Shares, directly or through a DTC broker or custodian, from which they can be traded directly on Nasdaq). As the Company is assigned to the Equity Shares (Transition) category of the Official List, no shareholder approval is required for the London Delisting. The Company has prepared an FAQ document for shareholders, which is available at Shareholder FAQ. Takeover Code The Takeover Code (the "Code") applies to any company which has its registered office in the U.K., the Channel Islands or the Isle of Man if any of its equity share capital or other transferable securities carrying voting rights are admitted to trading on a U.K. regulated market, a U.K. Multilateral Trading Facility ("MTF"), or a stock exchange in the Channel Islands or the Isle of Man. The Code therefore currently applies to the Company as its Ordinary Shares are admitted to trading on the LSE, which is a U.K. regulated market. The Code also applies to any company which has its registered office in the U.K., the Channel Islands or the Isle of Man if any of its securities were admitted to trading on a U.K. regulated market, a U.K. MTF, or a stock exchange in the Channel Islands or the Isle of Man at any time during the preceding two years. Accordingly, if the London Delisting becomes effective, the Code will continue to apply to the Company for a period of two years after the London Delisting, following which the Code will cease to apply to the Company. While the Code continues to apply to the Company, a mandatory cash offer will be required to be made if either: (a) any person acquires an interest in Ordinary Shares which (taken together with the Ordinary Shares in which the person or any person acting in concert with that person is interested) carry 30% or more of the voting rights of the Company; or (b) any person, together with persons acting in concert with that person, is interested in Ordinary Shares which in the aggregate carry not less than 30% of the voting rights of a Company but does not hold Ordinary Shares carrying more than 50% of such voting rights and such person, or any person acting in concert with that person, acquires an interest in any other Ordinary Shares which increases the percentage of Ordinary Shares carrying voting rights in which that person is interested. Brief details of the Takeover Panel (the "Panel"), and of the protections afforded by the Code, are set out in Appendix 2 to this announcement. |
Posted at 24/4/2025 07:27 by misca2 Indivior Announces Q1 2025 Financial Results24/04/2025 7:00am PR Newswire (US) Indivior (LSE:INDV) Thursday 24 April 2025 SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: hxxps://edge.media-s Participants may access the presentation telephonically by registering with the following link: hxxps://register-con (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on̷ Cision View original content to download multimedia: SOURCE Indivior PLC |
Posted at 04/3/2025 07:05 by waldron Indivior PLC Indivior PLC Files 2024 Annual Report on Form 10-K INDV +0.00%RNS Regulatory News - Today @ 07:00 Indivior PLC Files 2024 Annual Report on Form 10-K Richmond, VA, March 4, 2025 - Indivior PLC (NASDAQ/LSE: INDV) filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission ("SEC") on March 3, 2025. The Annual Report on Form 10-K is now available at www.sec.gov and under the "Investors" section of the Company's website (www.indivior.com). |
Posted at 27/2/2025 07:28 by bulltradept Not for the departing CEO it's not.Hopefully, but what can a new guy do to help INDV? The last RNS warned specifically about other firms competing. |
Posted at 20/2/2025 07:46 by waldron Indivior Announces FY and Q4 2024 Financial Results20/02/2025 7:00am PR Newswire (US) Indivior (LSE:INDV) Intraday Stock Chart Thursday 20 February 2025 Click Here for more Indivior Charts. SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: hxxps://edge.media-s Participants may access the presentation telephonically by registering with the following link: [...] (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on̷ Cision View original content to download multimedia: SOURCE Indivior PLC |
Posted at 24/10/2024 12:22 by the grumpy old men Ian LyallPROACTIVENEWS Indivior shares motor 11% after reassuring update; brokers positive Published: 11:50 24 Oct 2024 BST Indivior PLC (LSE:INDV)’s share price jumped 11% after the company reaffirmed its full-year outlook despite recent challenges, including increased competition for its opioid addiction treatment, Sublocade. In its third-quarter results, Indivior posted a 13% revenue increase to $307 million, with Sublocade sales rising 14% to $191 million. The company addressed concerns over competitor Brixadi, stating it remains confident in Sublocade's leadership, which holds a mid-60% market share in key prescribing groups. CEO Mark Crossley highlighted Sublocade’s differentiation, particularly in combating synthetic opioids, and reaffirmed the goal of achieving over $1.5 billion in peak revenue. Indivior is also streamlining its operations, aiming to cut operating expenses by up to $20 million in 2025. "Headline [third quarter figures beat consensus due to strong Suboxone Film but Sublocade growth is flat QoQ [quarter-on-quarter] In late morning trade, the stock was up 74.5p at 725p. Jefferies says 'buy' up to 1,800p. Fellow American bank Stifel restated its 'buy' and 1,400p price target, adding: "We are encouraged by the still more than 60% share for Sublocade by co-prescribers of both Sublocade and Brixadi, while the early and within-expectations settlement of the remaining antitrust cases is incrementally positive. "After two profit warnings this year, we recognise the need to rebuild market confidence, but continue to believe market concerns implied by current low multiples...are overdone." |
Posted at 10/10/2024 18:49 by waldron Benjamin ChiouSharecast News 10 Oct, 2024 17:01 Europe close: Stocks inch lower after choppy session Thursday saw choppy trading across European stock markets with the region's main benchmark finishing lower but moving within a narrow range, as investors focused on mixed economic data from the US and developments in the Middle East. The Stoxx 600 index closed down 0.18% (0.94 points) at 519.11, with less than four points separating the intraday high (521.08) and low (517.81). Wall Street stocks got off to a weak start after inflation and jobless claims data blurred the outlook for the next Federal Reserve policy decision. Following last week's bumper payroll report, markets had begun to lower their expectations for another big rate cut from the Fed. But data out on Thursday showed that jobless claims had jumped to their highest since June 2023, reviving hopes that more policy action could be on the cards to ease the strain on the economy. Nevertheless, figures showed that the annual rate of US consumer price inflation slowed to a three-and-a-half-yea Meanwhile, oil prices were once again on the rise as tensions in the Middle East continued to escalate. Brent was up 2.1% at $78.19 a barrel by the close in Europe, after having pulled back sharply over recent days since topping the $80 mark on Monday. “It looks increasingly likely that Israel will go for a large-scale attack on Iran, as reports emerge of Gulf states lobbying the US to rein in its ally," said Chris Beauchamp, chief market analyst at IG. "Oil prices have surged on hints that Israel is seeking to take advantage of the Iranian attack to deliver a major strike on its opponent. The consequences of that could include a closing of the Straits of Hormuz, leading to major disruption to oil supplies.” Back in Europe, data showed that retail sales in Germany rose over the past two months. According to delayed data from the Federal Statistical Office, sales volumes increased by 1.6% during August, following a 1.5% gain in July and a 1.1% decline in June. Destatis released figures for the past three months in one go on Thursday after suspending a number of key economic indicators in May due to a failed IT systems update at the Wiesbaden-based authority. Market movers GSK was among the best performers on the Stoxx 600, rising 3% after the London-listed pharma giant agreed to settle about 93% of US cases in its Zantac lawsuits for up to $2.2bn. The settlement figure was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price. Deutsche Telekom rose 2% on plans to lift its dividend and buy back shares on the back of better revenue expectations in the next three years. Leading the fallers was UK pharma firm Indivior after delivering its second profit warning this year. Shares were down 19% after Indivior said it was seeing faster initial adoption among treatment providers of a competing long-acting injectable to its Sublocade treatment, as it cut its full-year sales and earnings targets |
Posted at 10/8/2024 06:59 by misca2 Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action LawsuitAugust 09, 2024 at 09:54 pm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders (“OUD”) and serious mental illnesses. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Invidior PLC (INDV) Misled Investors Regarding the Financial Prospects of its Products According to the complaint, during the class period, defendants: (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (iii) knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY2024 net revenue guidance, including FY2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS. On July 9, 2024, Indivior issued a press release "announc[ing] a business update encompassing [its] outlook for [second quarter (‘Q2’)] and FY2024 financial performance." The July 9 Update reduced FY 2024 (i) total net revenue guidance to $1.15-$1.215 billion from the previous ranges of $1.24-$1.33 billion; (ii) SUBLOCADE net revenue guidance to $765-$805 million from the previous range of $820-$880 million; and (iii) OPVEE net revenue guidance to $9-14 million from the previous range of $15-25 million. The July 9 Update also shockingly advised that the Company would immediately cease all sales and marketing activities related to PERSERIS. On this news, Indivior's stock price fell $5.15 per share, or 33.57%, to close at $10.19 per share. What Now: You may be eligible to participate in the class action against Invidior PLC. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by October 1, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Invidior PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View source version on businesswire.com: |
Posted at 12/3/2022 17:05 by typo56 The news is quite possibly a continuation of this from 23 Feb.."Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction. People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company." Good or bad for the INDV share price? You decide! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
